About the Company
Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CLVS News
Why Clovis Oncology (CLVS) Stock is Dropping Today
Clovis Oncology (CLVS) stock is continuing to slide on Monday after the FDA questioned its lung cancer drug Friday. An advisory panel is slated to vote on the drug tomorrow. Clovis Oncology (CLVS ...
Why Clovis Oncology (CLVS) Stock Hit a One-Year Low Today
NEW YORK -- Clovis Oncology continued to plunge to a one-year low of $38.48 on Tuesday with another day of double-digit declines following disappointing data from ASCO 2014 with regard to the ...
Clovis Oncology
Clovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved and on the market in less than a decade. Clovis hopes to get ahead of rivals in prostate ...
Ulta surprises Fresno, Clovis hospital staff with free products
Over 600 bags of Ulta Beauty products were handed out to staff from both Clovis Community Hospital and Community Regional ...
Buildings evacuated due to gas leak in Clovis
Clovis police and firefighters are at a commercial building after a gas leak was reported.It happened at Shaw and Villa ...
David M Mott's Net Worth
Who is David M Mott? David M Mott has an estimated net worth of $2.21 Billion. This is based on reported shares across multiple companies, which include PhaseBio Pharmaceuticals Inc, Ra ...
Harry R Weller's Net Worth
Who is Harry R Weller? Harry R Weller does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ...
Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous ...
ELEV Elevation Oncology, Inc.
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
Pyxis Oncology, Inc. (PYXS)
Sullivan, M.D BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to ...
Clovis Oncology
Clovis Oncology has said it may not have enough cash to fund continuing operations beyond January next year, as it struggles to reverse a decline in sales of PARP inhibitor Rubraca. NICE has ...
Clovis Oncology
This page shows the latest Clovis Oncology news and features for those working in and with pharma, biotech and healthcare. Dave Fredrickson, executive vice president, AZ’s oncology business unit. ...
Loading the latest forecasts...